Medicinal product name Blincyto
Pharmaceutical form Powder for concentrate and solution for solution for infusion
Strength 38.5 μg 
Information from the MAH on shortages Not notified
Availability of medicinal product
Product No.Package sizeWholesalers' stock state
EU/1/15/1047/001N1 Is available
Legal status Rx Prescription (Pr.II onk. ķīm. ter., hem.)
Summary of product characteristics, package leaflet and labeling text  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website
Risk minimisation measuresIzglītojošie materiāli ārstam Izglītojošie materiāli ārstam
Izglītojošie materiāli farmaceitam Izglītojošie materiāli farmaceitam
Izglītojošie materiāli pacientam Izglītojošie materiāli pacientam
Vēstule veselības aprūpes speciālistam Vēstule veselības aprūpes speciālistam
Conclusion on the therapeutic and cost effectiveness of medicines Jun 20, 2022 C91.0
 Jul 13, 2022 C91.0
ATC code L01FX07 Antineoplastic agents

Medicinal products (1)

Availability of medicinal product Wholesalers Package size, content Primary packaging Maximum admissible pharmacy price (€ incl. VAT) Product No. Labelling
 Is available (according to the information provided by wholesalers)
(2 containers)
Tamro N1
(38,5 µg/10 ml)
Glass vial and vial 3633.53  EU/1/15/1047/001  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website

Registration information

Marketing authorisation No. EU/1/15/1047/001
Date of authorisation Nov 23, 2015
Marketing authorisation holder, country Amgen Europe B.V., Netherlands